Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 1;203(5):635-637.
doi: 10.1164/rccm.202007-2740LE.

Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity

Solomon P le Roux  1 , Caryn Upton  1 , Naadira Vanker  1 , Kelly E Dooley  2 , Andreas H Diacon  3 ; A5312 Study Team
Collaborators, Affiliations
Comment

Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity

Solomon P le Roux et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Daily log10 colony-forming units (log10CFUs) and log10 time to positivity (log10TTP) for mycobacteria over 7 days for all 59 participants. The relationship between TTP and CFUs is determined using an ordinary least-squares regression model: TTP = b0 + b1 × CFUs. The resulting equation is log10TTP = 2.663 – 0.0854 × log10CFU; r2 = 0.555; P < 0.0001 for b0 and b1.
Figure 2.
Figure 2.
Daily log10 colony-forming units (log10CFU) and log10 time to positivity (log10TTP) for mycobacteria over 7 days for all 59 participants with mutated (black dots) and nonmutated (red crosses) bacteria. The model includes a mutation variable (0, dashed line, or 1, full line): TTP = b0 + b1 × CFUs + b2 × mutations + b3 × CFUs × mutations. This formula resulted in log10TTP = 2.6324 – 0.0947 × log10CFUs + 0.1133 × mutations – 0.0013 × log10CFUs × mutations; r2 = 0.631; P < 0.0001 for b0, b1; P = 0.002 for b2; P = 0.852 for b3.
See this image and copyright information in PMC

Comment on

References

    1. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, et al. A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug-resistant TB (INHindsight): a randomized open-label clinical trial. Am J Respir Crit Care Med. 2020;201:1416–1424. - PMC - PubMed
    1. O’Sullivan DM, McHugh TD, Gillespie SH. Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol. 2010;59:1533–1535. - PubMed
    1. Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evol Appl. 2015;8:273–283. - PMC - PubMed
    1. Rifat D, Campodónico VL, Tao J, Miller JA, Alp A, Yao Y, et al. In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D. Future Microbiol. 2017;12:753–765. - PMC - PubMed
    1. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, et al. Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA) Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1:462–470. - PubMed

LinkOut - more resources